

14th National Symposium on Inflammatory Bowel Diseases

5th Franco - Romanian Meeting
Crowne Plaza Bucharest
15th - 17th of September



Symposium
2022
HYBRID





Dear friends,

This year`s congress will be held under the auspices of normality, after more than two years of COVID pandemic. We all had to face unprecedented challenges, but as in any crisis there are also opportunities, it was an opportunity to develop the national register of inflammatory bowel diseases (in the spirit of the accelerated digitalization of medicine), to participate in the creation of guidelines for treatment and vaccination, to take a more serious look at the patient reported outcomes scores (and I recommend you to see the posters on this topic).

As usual, we have this year our French colleagues for the fifth edition of the already classic French-Romanian course on inflammatory bowel diseases. It is going to be an extremely interesting course, centered on clinical cases and tips and tricks and I am sure of its success.

This year`s program of the congress is very promising and given that we now have access to almost all the new molecules, I think it will be an opportunity to recapitulate the treatment guidelines and to adopt on a large scale the personalized therapy centered on the specific patient need.

The efforts for the national registry must continue and I am very happy that starting this year will have a stronger collaboration with pediatric gastroenterologists and they will join us in order to build the registry especially with the increased incidence of IBD in pediatric population. I hope that soon we will be able to see the first publications with the Romanian experience in IBD- the effectiveness of new therapies in real life, up-to-date epidemiological data, the cost effectiveness of therapy, adherence to treatment and the list can go on. I think that such a registry will be of great help, including in the shaping of health policies in the future.

I want to thank the industry for their institutional and academic support. I think they have an important role in supporting medical education and it is a joint effort to insure access to tests and therapies for our patients.

Last but not least, I want to thank you dear colleagues for the involvement and effort you make every day in the service of the IBD patients.

A fruitful and interesting congress!

Congress President
Lucian Negreanu

RCCC Annual Meeting, 15th-17th of SEPTEMBER 2022

The 5th Franco - Romanian Meeting

International Faculty

Matthieu Allez

Franck Carbonnel

Philippe Seksik

Mathieu Uzzan

National Faculty

Simona Bătagă

Ciprian Brisc

Cristina Cijevschi

Mihai Ciocîrlan

Tudorel Ciurea

Gabriel Constantinescu

Adina Croitoru

Mircea Diculescu

Daniela Dobru

Dan Dumitraşcu

Eugen Dumitru

Dan Gheonea

Cristian Gheorghe

Liana Gheorghe

Adrian Goldiş

Răzvan Iacob

Mirela Ionescu

Sevastita Iordache

Mariana Jinga

Bogdan Mateescu

Mircea Mănuc

Cătălina Mihai

Lucian Negreanu

Corina Pop

Carmen Preda

Ioan Rogoveanu

Andrada Seicean

Anamaria Singeap

Oana Stănciulea

Alina Tanţău

Marcel Tanţău

Anca Trifan

Opening ceremony (Lucian Negreanu, Mircea Diculescu)

Franco-Romanian Meeting

08:45 – 09:00 Introduction (Matthieu Allez, Mircea Diculescu)

09:00 – 10:30 Session I: Crohn's disease always a challenge

Chairs: Lucian Negreanu, Franck Carbonnel

1. Clinical case: Challenges in Crohn's disease (Tudor Stroe, Mircea Diculescu)
2. Clinical case: Lost and found: a complex case of CD (Andreea Dobromirescu – live from Beziers)
3. The Crohn wars: Never Give Up Hope, No Matter How Dark Things Seem (Cristina Tocia)
4. Therapeutic strategy in IBD: a four step approach on therapeutic strategy in IBD: a user's guide (Franck Carbonnel)
5. Nutrition and IBD: from epidemiology to therapeutics (Franck Carbonnel)

10:30 – 10:45 Educational session organized by RCCC with the support of Innergy

The therapeutic connection between microbiota modulation and inflammatory bowel diseases

Speaker: Dan Gheonea



10:45 – 11:15 Educational session organized by RCCC with the support of Ewopharma

Proven Clinical efficacy of adalimumab biosimilar observed in clinical practice, from patient cases with IBD

Speaker: Mircea Diculescu, Adrian Goldiș



11:15 – 11:45 Coffee break

11:45 – 13:15 Session II: Severe Ulcerative Colitis

Chairs: Adrian Goldiș, Mathieu Uzzan

1. Fulminant ulcerative colitis - still a challenge for the clinical practice (Anca Trifan, Ana-Maria Singeap, Oana Timofte, Oana Petrea)
2. Fulminant Ulcerative Colitis in a young patient. Always a decision challenge (Camelia Foncea, Tudor Moga, Adrian Goldiș)
3. Clinical case: Severe ulcerative colitis: can we reach our goals with new available therapies? (Corina Meianu, Mircea Diculescu)
4. Are the new guidelines really changing the treatment of UC? (Adrian Goldiș)
5. Medical strategies for steroids-refractory acute severe colitis: beyond ciclosporin and infliximab (Mathieu Uzzan)

13:15 – 13:45 Educational session organized by RCCC with the support of Sandoz

Safety and benefits of biosimilars non-medical switch: from clinical studies to Real World Evidence Data

Speakers: Lucian Negreanu, Dan Gheonea



13:45– 14:45 Lunch

14:45 – 15:15 Educational session organized by RCCC with the support of Pfizer

Weighing up treatment options in UC: how do we interpret the evidence for JAK inhibition?

Speakers: Lucian Negreanu, Mircea Diculescu



15:15 – 16:45 Session III: From pregnancy to pediatric IBD

Chairs: Cătălina Mihai, Philippe Seksik

1. The management of pregnant IBD patient (Cătălina Mihai, Cristina Cijevschi)
2. Ulcerative colitis flare-up during pregnancy: clinical challenges (Bogdan Ungureanu, Irina Doica)
3. Managing pregnancy in anoperineal Crohn's disease: from conception to birth (Carmen Ștefănescu, Manon Haas)
4. Setting the scene in pediatric IBD! (Iulia Tincu, Luiza Bordei, Lucica Galeș, Loredana Dobrescu, Anca Avram, Cristian Ioan Nedelcu)
5. Delayed Crohn disease diagnosis - can we face the consequences? (Iulia Tincu, Luiza Bordei, Lucica Galeș, Loredana Dobrescu, Anca Avram, Cristian Ioan Nedelcu)

16:45 – 17:00 Coffee Break

17:00 – 18:30 Session IV: Special issues in elderly with IBD

Chairs: Dan Gheonea, Matthieu Allez

1. IBD in senior patients (Dan Nicolae Florescu, Dan Gheonea)
2. Clinical Case – Sixty is the new forty-diagnosing IBD in a senior (Mihai Pahomeanu, Lucian Negreanu)
3. Clinical Case – Elderly with UC and comorbidities: management challenges (Otilia Gavrilescu, Mihalea Dranga, Cătălina Mihai, Cristina Cijevschi)
4. Clinical Case – The role of ozone therapy as adjuvant treatment in IBD elderly patients (Adriana Botezatu, Nicolae Bodrug)
5. Clinical Case (Matthieu Allez)

18:30 – 18:45 Educational session organized by RCCC with the support of Nestle

Modern solutions for enteral nutrition and nutritional deficiencies compensation for IBD patients

Speaker: Dan Gheonea



18:45 – 19:00 Conclusions of the meeting (Lucian Negreanu, Matthieu Allez)

19:15 Welcome Dinner organized by RCCC



08:00 – 9:15 Session I: New trends in IBD – Romanian Registry of IBD

Chairs: Dan Gheonea, Lucian Negreanu, Cătălina Mihai

1. Prevalence and challenges in pediatric population (Iulia Tincu)
2. Current situation of the registry, apps and wearables (Dan Gheonea)
3. Situation in the Nord-East of Romania (Cătălina Mihai, Otilia Gavrilesco, Cristina Cijevschi, Sebastian Zenovia, Ana Maria Singeap, Anca Trifan)
4. What about the south east? (Cristina Tocia)
5. Panel discussions

09:15 – 10:30 Session II: Surgery in IBD – Why?, How?, When?

Chairs: Cristian Gheorghe, Bogdan Mateescu, Oana Stănciulea

1. Current trends in surgical management of IBD (Oana Stănciulea, I Mosteanu, R Ciortan F Loai Alshantti, I Popescu)
1. Inflammatory disorders of the ileal pouch after restorative proctocolectomy for UC (Cristian Gheorghe)
2. What's new in the postoperative medical treatment of CD after ileocolic resection (Anca Dimitriu)
3. The approach to perianal fistula in CD (Bogdan Mateescu)
4. Q&A

10:30 – 11:30 Educational session organized by RCCC with the support of Takeda

A new ERA in gastroenterology

Chairman: Lucian Negreanu

Speakers: Lucian Negreanu, Mircea Diculescu, Cristian Gheorghe



11:30 – 12:00 Coffee Break

12:00 – 13:00 Session III: Endoscopy and ultrasound session

Chairs: Gabriel Constantinescu, Marcel Tanțău, Eugen Dumitru

1. Monitoring disease activity and endoscopic healing as a treatment target in UC (Cristina Tocia)
2. Surveillance endoscopy in IBD (Marcel Tanțău)
3. Endoscopy for therapeutic intervention of IBD (Gabriel Constantinescu)
4. Insights into the role of gastrointestinal ultrasound in IBD (Sevastita Iordache)

13:00 – 14:00 Educational session organized by RCCC with the support of Janssen

Stelara redefines expectations in IBD

Speakers: Liana Gheorghe, Lucian Negreanu



14:00 – 15:00 Lunch Break

15:00 – 16:30 Session IV: Management of extraintestinal manifestations in IBD

Chairs: Liana Gheorghe, Alina Tanțău, Adrian Goldiș

1. Extraintestinal manifestations (EIMs) in IBD – short overview (Liana Gheorghe)
2. Stones, bones and joints: Management of musculoskeletal EIMs and lithiasis in patients with IBD (Roxana Zaharie, Alina Tanțău)
3. What lies into the skin, mucosa and eye: Management of cutaneo-mucosal EIMs in patients with IBD (Daniela Lazăr, Adrian Goldiș)
4. Bowel – liver crosstalk: Primary sclerosing colangitis in IBD patients (Răzvan Iacob)
5. Are my extraintestinal symptoms due to IBD therapy? Management of extraintestinal complications of medication (Ana-Maria Singeap, Anca Trifan)
6. Take home messages (Alina Tanțău, Adrian Goldiș)
7. Q&A

16:30 – 17:00 State of the Art Lecture: 2022 - Mucosal healing in IBD - Quo Vadis? (Cristina Cijevschi)

17:00-17:30 Educational session organized by RCCC with the support of Sandoz

Probiotics and barrier function in colitis and irritable bowel syndrome

Speaker: Liana Gheorghe



17:30 – 18:00 Coffee break

18:00 – 19:30 Session V: Challenges in complex IBD cases

Chairs: Mircea Mănuș, Andrada Seicean, Cristina Cijevschi

1. Management of patients with Crohn's disease and complex fistulas (Andreea Chifulescu, Carmen Preda)
2. Therapeutic challenges in BC with over 20 years of evolution (Mihaela Dranga, Cristina Cijevschi)
3. Side effects related to biological therapy for Inflammatory bowel diseases (Voicu Rednic, Andrada Seicean)
4. Q&A

20:00 Collegial Meeting organized by RCCC



08:00 – 09:00 Session VI: Original research in IBD

Chairs: Cora Pop, Ciprian Brisc, Mircea Diculescu

1. Fecal calprotectin in ulcerative colitis: friend or foe? (Raluca Rafti, Marilena Mușat, Andrei Dumitru, Anamaria Trandafir, Elena Dina, Luana Alexandrescu, Eugen Dumitru, Cristina Tocia)
2. Assessment of ileal crohn's disease activity by gastrointestinal ultrasound and MR-enterography: a feasibility study (Răzvan-Cristian Statie, Dan Ionuț Gheonea, Sevastița Iordache, Dan Nicolae Florescu, Lucian-Mihai Florescu, Tudorel Ciurea)
3. Fatigue and Health-related Quality of Life in Patients with Inflammatory Bowel Disease with Inactive Disease (Tudor Stroie, Corina Meianu, Roxana Lucuta, Alexandra Scutaru, Mircea Diculescu)
4. The role of capsule endoscopy in the diagnosis of isolated small bowel Crohn's disease (Ana-Maria Sîngeap, Anca Trifan, Dana Petrea, Cătălin Sfarti, Laura Huiban, Irina Gîrleanu, Cristina Muzica, Carol Stanciu)
5. Screening for liver steatosis and fibrosis in patients with inflammatory bowel disease (Remus Stafie, Carol Stanciu, Adrian Rotaru, Sebastian Zenovia, Ermina Stratina, Robert Nastasa, Ana Maria Sîngeap, Camelia Cojocariu, Cătălin Sfarti, Irina Gîrleanu, Ștefan Chiriac, Tudor Cuciureanu, Laura Huiban, Cristina Muzica, Anca Trifan)
6. Bowel Ultrasonography and Computed Tomography tell the same story using different languages in analyzing Crohn`s disease lesions (Anda Leș, Ana-Maria Sârbu, R. Dumitru, Roxana Costache, Liana Gheorghe and C. Gheorghe)

09:00 – 10:00 Session VII: Nutrition and IBD

Chairs: Mircea Mănuș, Ana-Maria Sîngeap, Carmen Preda

1. Nutritional interventions in IBD: Basic principles (Georgiana Gâlcă Blănariu, Gabriela Ștefănescu, Anca Trifan)
2. Induction of remission in Crohn's disease: efficacy of Crohn's disease exclusion diet (Daniela Șerban, Georgiana Tita)
3. Role of an exclusion diet (reduced disaccharides, saturated fats, emulsifiers, red and ultraprocessed meats) in maintaining the remission of chronic inflammatory bowel diseases in adults (Carmen Preda, Doina Istrățescu, Teodora Manuș, Tudor Stroie, Mircea Mănuș, Mircea Diculescu)
4. Should you recommend a special diet in IBD in 2022? Pros and cons (Teodora Mănuș)

10:00-10:15 Educational session organized by RCCC with the support of Fresenius

From the critical patient with IBD to nutritional maintenance therapy

Speakers: Mircea Diculescu



10:15 – 11:30 Session VIII: Malignancy in IBD patients – how to deal with?

Chairs: Anca Trifan, Daniela Dobru, Bogdan Mateescu

1. Malignancies and IBD: the spectrum of the problem (Anca Trifan)
2. Intestinal cancers and IBD: risk assessment and how could we reduce the risk. (Ana Maria Sîngeap, Cristina Muzica)
3. The role of endoscopy in surveillance and treatment of CRC in IBD patients (Daniela Dobru)
4. IBD and hematological malignancies (Dana Stoica, Remus Stafie)
5. IBD and skin malignancies (Elena Toader)
6. Advanced therapies and neoplasms: risk-benefit assessment in patients with IBD (Monica State)
7. Management of IBD during cancer therapy (Camelia Cojocariu, Laura Huiban)
8. Conclusions (Daniela Dobru, Bogdan Mateescu)

11:30 – 12:00 Coffee Break

12:00 – 12:30 Educational session organized by RCCC with the support of Alfasigma
Rifaximin-alfa: a gut environment modulator in the management of inflammatory bowel diseases?

Chair: Mihai Mircea Diculescu

Speaker: Lucian Negreanu



12:30-12:45 Educational session organized by RCCC with the support of Medochemie
Functional dyspepsia between habit and innovation – itopride

Speaker: Mircea Diculescu



12:45 – 14:15 Session IX: Current therapeutic strategies in 2022

Chair: Liana Gheorghe, Lucian Negreanu, Dan Gheonea

1. Old agents: Aminosalicylates, corticosteroids and thiopurins – new data, revised indications, remaining controversis (Dan Gheonea)
2. Biologics in 2022: anti-TNF, anti-integrins and anti-IL12/23 agents (Alina Tanțău)
3. Small molecules: JAK inhibitors and S1P1 inhibitors (Eugen Dumitru)
4. Key-points of therapeutic strategy in IBD: getting the best from medication, treat-to-target and what to do if off-target, combination of biologics (Liana Gheorghe)
5. Treatment Patterns in Inflammatory Bowel Disease Patients in a Tertiary Gastroenterology Center (Roxana Saizu, Anda Leș, I A Saizu, C Gheorghe)
6. Quality of life in Inflammatory Bowel Diseases – Is the flare all that matters? (Mihaela Topală, Victor Ionescu, Răzvan Iacob, Cristian Gheorghe)
7. Q&A Discussions

14:15 – 14:45 Review of best articles (Liana Gheorghe)

14:45 – 14:55 Conclusions (Lucian Negreanu, Dan Gheonea)

14:55 – 15:00 RCCC General Assembly





**MONOTERAPIE CU
EFICACITATE ÎNALTĂ¹⁻⁶**



**PROFIL DE
SIGURANȚĂ SOLID⁴⁻⁶**



**FRECVENȚĂ REDUSĂ
ȘI FLEXIBILITATE A
ADMINISTRĂRII¹**

Doar **1**
doză de inducție IV

+

4-6
doze SC de
menținere anual¹

**Regimul confortabil
de menținere cu
administrare subcutanată**
vă oferă dumneavoastră și
pacientului libertatea de a
alege între administrarea la
domiciliu sau la clinică¹



**Stelara[®] face posibilă remisiunea de durată la pacienții
cu boală Crohn^{5,7}**

IV, intravenos; SC, subcutanat

1. Rezumatul caracteristicilor produsului Stelara[®], ultima variantă revizuită. 2. Feagan BG et al. N Eng J Med. 2016; 375:1946-1960. 3. Danese S, et al. Abstract DOP54 presented at European Crohn's and Colitis Organisation (ECCO) 14th Congress, 4. Pauwels A, et al. Poster P0414 presented at European Crohn's and Colitis Organisation (ECCO) 14th Congress, 6-9 March 2019, Copenhagen, Denmark. 5. Hanauer SB, et al. J Crohns Colitis. 2020; 14: 23-32. 6. Sands BE, et al. N Eng J Med. 2019; 381: 1201-1214. 7. Sandborn WJ et al. United European Gastroenterology Week 2020 (abstract ID A-1150-0059-01563).

SANDOZ A Novartis Division

LIDER GLOBAL ÎN BIOSIMILARE

Erelzi
etanercept

Hyrimoz
adalimumab

Rixathon
rituximab

Zessly
infliximab



SensoReady[®]
pen



Acest material promoțional este destinat profesioniștilor din domeniul sănătății. Aceste medicamente se eliberează pe bază de prescripție medicală restrictivă întocmită de medicul specialist. Pentru informații detaliate de prescriere, vă rugăm consultați Rezumatul Caracteristicilor Produsului, disponibil la cerere.

SANDOZ A Novartis
Division


Sandoz S.R.L. - Calea Floreasca nr. 169A, clădirea A, et. 1, sect. 1, București, România
Tel.: +40 21 407 51 60 • Fax: +40 21 407 51 61 • medical.ro@sandoz.com • www.sandoz.ro
Farmacovigilență: drugsafety.romania@novartis.com • Fax: +40 21 310 40 29

ART-VAR-07/22-09



Corectează disbioza prin modularea microbiotei intestinale!

Acest material promoțional este destinat profesioniștilor din domeniul sănătății. Normix 200 mg comprimate filmate se eliberează pe bază de prescripție medicală PRF. Administrare orală. Pentru informații suplimentare vă rugăm să consultați rezumatul caracteristicilor produsului complet, disponibil la cerere sau pe site-ul www.anm.ro. Profesioniștii din domeniul sănătății sunt rugați să raporteze orice reacție adversă suspectată sau reclamare cu privire la acest produs la adresa de e-mail: Drugsafety@alfasigma.ro sau la Agenția Națională a Medicamentului și a Dispozitivelor Medicale din România www.anm.ro. DAPP - Alfasigma S.p.A.



A series of horizontal dotted lines spanning the width of the page, intended for writing or drawing.

Sponsors

